Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease

Neurology

Volumn 63, Issue 10, 2004, Pages 1912-1917

  Hochstrasser, H ^a   Bauer, P ^a   Walter, U ^d   Behnke, S ^e   Spiegel, J ^e   Csoti, I ^f   Zeiler, B ^e   Bornemann, A ^b   Pahnke, J ^g   Becker, G ⁱ   Riess, O ^a   Berg, D ^a,c,h  

^a Institute for Human Genetics   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; IRON;

ADULT; AGED; ARTICLE; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; CP GENE; DOPPLER ECHOGRAPHY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENE; GENE MUTATION; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRON BLOOD LEVEL; IRON METABOLISM; IRON TRANSPORT; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 5444246509     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000144276.29988.C3     Document Type: Article

References (35)

1. Berg D, Becker G, Riederer P, Riess O. Iron in neurodegenerative disorders. Neurotox Res 2002;4:637-653.
2. Berg D, Gerlach M, Youdim MBH, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001;79:225-236.
3. Gasser T. Overview of the genetics of parkinsonism. Adv Neurol 2003;91:143-152.
4. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
5. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.
6. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002;109:191-196.
7. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-1031.
8. Berg D, Grote C, Rausch W-D, et al. Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 1999;25:901-904.
9. Berg D, Roggendorf W, Schröder U, et al. Echogenicity of the substantia nigra-association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
10. Felletschin B, Bauer P, Walter U, et al. Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 2003;352:53-56.
11. Qian ZM, Ke Y. Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Rev 2001;35:287-294.
12. Klomb LWJ, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 1996;5:1989-1996.
13. Kohno S, Miyajima H, Takahashi Y. Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 1999;2:237-238.
14. Hellmann NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439-458.
15. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 2002;22:6578-6586.
16. Kim KS, Choi SY, Kwon HY, Won MH, Kang TC, Kang JH. The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 2002;84:625-631.
17. Patel BN, Dunn RJ, David S. Alternative RNA splicing generates a glycophosphytidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 2000;275:4305-4310.
18. Jeong SY, David S. Glycophosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003;278:27144-17148.
19. Patel BN, David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997;272:20185-20190.
20. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363-365.
21. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Giltin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-2543.
22. Harris ZL, Durley AP, Man TK, Giltin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999;96:10812-10817.
23. Mukhopadhyay CK, Attieh ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science 1998;279:714-717.
24. Miyajima H, Kohno S, Takahashi Y, Sugimoto M, Sakamoto M, Skai N. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001;26:2205-2210.
25. Bosio S, De Gobbi M, Roetto A, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002;100:2246-2248.
26. Tajima K, Kawanami T, Nagai R, Horiuchi S, Kato T. Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain. Neurology 1999;53:619-622.
27. Münch G, Lüth H, Wong A, et al. Crosslinking of α-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000;20:253-257.
28. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 1999;10:717-721.
29. Kohno S, Miyajima H, Takahashi Y, Suzuki H, Hishida A. Defective electron transfer in complex I and IV in patients with aceruloplasminemia. J Neurol Sci 2000;182:57-60.
30. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
31. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455.
32. Yoshida K, Kaneko K, Miyajima H, et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 2000;175:91-95.
33. Miyajima H, Kohno S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002;29:433-438.
34. Boll M-C, Sotelo J, Otero E, Alcaraz-Zubeldia M, Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Let 1999;265:155-158.
35. Torsdottir G, Kristinsson J, Sveinbjornsdottir S, Snaedal J, Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999;85:239-243.